Mersana Therapeutics Ownership | Who Owns Mersana Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Mersana Therapeutics Ownership Summary

Mersana Therapeutics is owned by 61.90% institutional investors, 1.46% insiders, and 36.63% retail investors. Nextech invest is the largest institutional shareholder, holding 9.83% of MRSN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.78% of its assets in Mersana Therapeutics shares.

MRSN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Mersana Therapeutics	61.90%	1.46%	36.63%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Nextech invest	12.07M	9.83%	$17.26M
Bain capital life sciences investors	8.66M	6.95%	$2.56M
Blackrock	8.38M	6.90%	$16.85M
Vanguard group	7.06M	5.75%	$10.09M
Rock springs capital management lp	3.81M	3.06%	$1.13M
Blackrock funding, inc. /de	3.76M	3.02%	$1.11M
Silverarc capital management	3.13M	2.51%	$926.01K
Acadian asset management	2.96M	2.37%	$873.00K
State street	2.68M	2.21%	$5.39M
Jpmorgan chase	2.53M	2.07%	$3.62M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Nextech invest	12.07M	2.80%	$17.26M
Lion point capital, lp	644.00K	1.41%	$221.66K
5am venture management	1.30M	0.45%	$1.87M
Bain capital life sciences investors	8.66M	0.32%	$2.56M
Silverarc capital management	3.13M	0.17%	$926.01K
Clarivest asset management	500.50K	0.10%	$1.01M
Luminus management	1.04M	0.08%	$307.64K
Rock springs capital management lp	3.81M	0.07%	$1.13M
683 capital management	1.99M	0.04%	$589.04K
Bridgeway capital management	475.50K	0.02%	$955.75K

Top Buyers

Holder	Shares	% Assets	Change
Luminus management	1.04M	0.08%	1.04M
Lion point capital, lp	644.00K	1.41%	644.00K
683 capital management	1.99M	0.04%	340.00K
Blackrock	8.38M	0.00%	288.18K
Bridgeway capital management	475.50K	0.02%	243.20K

Top Sellers

Holder	Shares	% Assets	Change
Ecor1 capital	-	-	-11.33M
Blackrock funding, inc. /de	3.76M	-	-4.56M
Novo	-	-	-4.25M
Vr adviser	-	-	-3.57M
State street	2.68M	0.00%	-2.82M

New Positions

Holder	Shares	% Assets	Change	Value
Luminus management	1.04M	0.08%	1.04M	$307.64K
Lion point capital, lp	644.00K	1.41%	644.00K	$221.66K
Callan family office	56.56K	0.00%	56.56K	$16.74K
China universal asset management	26.19K	0.00%	26.19K	$37.46K
Two sigma securities	17.57K	0.00%	17.57K	$5.20K

Sold Out

Holder	Change
Farther finance advisors	-1.00
Ifp advisors	-2.00
Frazier financial advisors	-5.00
Capital performance advisors llp	-11.00
Nelson, van denburg & campbell wealth management group	-22.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	81	-27.03%	77,176,495	-12.25%	61	1.22%	35	-36.36%	30	-3.23%
Mar 31, 2025	7	-94.85%	17,769,330	-82.96%	14	0.20%	3	-95.16%	1	-97.50%
Dec 31, 2024	130	7.44%	101,397,402	-12.65%	82	0.92%	58	13.73%	39	21.88%
Sep 30, 2024	121	-3.20%	116,077,343	1.64%	94	1.07%	52	-17.46%	32	-11.11%
Jun 30, 2024	125	-2.34%	114,205,327	-2.80%	94	0.99%	63	-12.50%	36	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	3.47M	2.78%	-
Vanguard Total Stock Mkt Idx Inv	135.87K	2.72%	-2.97K
Vanguard Explorer Inv	2.01M	1.61%	-
Vanguard Institutional Extnd Mkt Idx Tr	1.52M	1.22%	-
Fidelity Small Cap Index	1.11M	0.89%	-
State St Russell Sm/Mid Cp® Indx NL Cl C	839.38K	0.67%	-
State St Russell Sm/Mid Cp® Indx SL Cl I	839.38K	0.67%	-
iShares Biotechnology ETF	625.00K	0.50%	-2.26K
iShares Russell 2000 ETF	569.31K	0.46%	-
Vanguard Russell 2000 ETF	564.71K	0.45%	4.82K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 16, 2025	Mandelia Ashish	VP, Chief Accounting Officer	Sell	$2.06K
Jan 16, 2025	Protopapas Anna	-	Sell	$5.01K
Jan 16, 2025	Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Sell	$4.67K
Jan 16, 2025	Huber Martin H. Jr.	President, CEO	Sell	$2.62K
Jan 16, 2025	DeSchuytner Brian	SVP, COO & CFO	Sell	$4.91K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	18
2024 Q4	-	11
2024 Q3	-	1
2024 Q2	-	-

MRSN Ownership FAQ

Who Owns Mersana Therapeutics?

Mersana Therapeutics shareholders are primarily institutional investors at 61.90%, followed by 1.46% insiders and 36.64% retail investors. The average institutional ownership in Mersana Therapeutics's industry, Biotech Stocks , is 306.59%, which Mersana Therapeutics falls below.

Who owns the most shares of Mersana Therapeutics?

Mersana Therapeutics’s largest shareholders are Nextech invest (12.07M shares, 9.83%), Bain capital life sciences investors (8.66M shares, 6.95%), and Blackrock (8.38M shares, 6.90%). Together, they hold 23.69% of Mersana Therapeutics’s total shares outstanding.

Does Blackrock own Mersana Therapeutics?

Yes, BlackRock owns 6.90% of Mersana Therapeutics, totaling 8.38M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 16.85M$. In the last quarter, BlackRock increased its holdings by 288.18K shares, a 3.56% change.

Who is Mersana Therapeutics’s biggest shareholder by percentage of total assets invested?

Nextech invest is Mersana Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.80% of its assets in 12.07M Mersana Therapeutics shares, valued at 17.26M$.

Who is the top mutual fund holder of Mersana Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Mersana Therapeutics shares, with 2.78% of its total shares outstanding invested in 3.47M Mersana Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools